{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T22:05:03Z","timestamp":1779487503886,"version":"3.53.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.maturitas.2026.108929","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T08:13:50Z","timestamp":1774599230000},"page":"108929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Menopausal hormone therapy in breast cancer survivors: A review"],"prefix":"10.1016","volume":"208","author":[{"given":"Lauren M.","family":"Granat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly J.","family":"Pederson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.maturitas.2026.108929_bb0005","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1001\/jama.2022.18625","article-title":"Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: US preventive services task force recommendation statement","volume":"328","author":"US Preventive Services Task Force","year":"2022","journal-title":"JAMA"},{"issue":"25","key":"10.1016\/j.maturitas.2026.108929_bb0010","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1161\/CIR.0000000000000912","article-title":"Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association","volume":"142","author":"El Khoudary","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.maturitas.2026.108929_bb0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bpobgyn.2022.03.002","article-title":"Bone and heart health in menopause","volume":"81","author":"Nash","year":"2022","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"issue":"5","key":"10.1016\/j.maturitas.2026.108929_bb0020","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.2022.24140","article-title":"Management of Menopausal Symptoms: a review","volume":"329","author":"Crandall","year":"2023","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.maturitas.2026.108929_bb0025","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of The North American menopause society","volume":"29","author":"\u201cThe 2022 Hormone Therapy Position Statement of The North American Menopause Society\u201d Advisory Panel","year":"2022","journal-title":"Menopause"},{"issue":"1","key":"10.1016\/j.maturitas.2026.108929_bb0030","first-page":"21","article-title":"British menopause society consensus statement on the management of estrogen deficiency symptoms, arthralgia and menopause diagnosis in women treated for early breast cancer. Post","volume":"25","author":"Marsden","year":"2019","journal-title":"Reprod. Health"},{"issue":"2","key":"10.1016\/j.maturitas.2026.108929_bb0035","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/GME.0b013e31826560da","article-title":"Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer","volume":"20","author":"Baumgart","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2026.108929_bb0040","article-title":"Management of vasomotor symptoms in cancer patients","volume":"30(2):oyaf002","author":"Zhu","year":"2025","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.maturitas.2026.108929_bb0045","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/GME.0000000000000374","article-title":"North central Cancer treatment group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes","volume":"22","author":"Park","year":"2015","journal-title":"Menopause"},{"issue":"1","key":"10.1016\/j.maturitas.2026.108929_bb0050","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/nu15010160","article-title":"The effect of vitamin E supplementation in postmenopausal women-a systematic review","volume":"15","author":"Feduniw","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.maturitas.2026.108929_bb0055","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/13697137.2020.1777965","article-title":"Cognitive behavioral therapy for menopausal symptoms","volume":"24","author":"Hunter","year":"2021","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2026.108929_bb0060","article-title":"Non-hormonal treatments for menopausal symptoms","volume":"359","author":"Hickey","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2026.108929_bb0065","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","article-title":"Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study","volume":"401","author":"Lederman","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.maturitas.2026.108929_bb0070","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11764-016-0585-9","article-title":"Vaginal and sexual health treatment strategies within a female sexual medicine program for cancer patients and survivors","volume":"11","author":"Carter","year":"2017","journal-title":"J. Cancer Surviv."},{"key":"10.1016\/j.maturitas.2026.108929_bb0075","article-title":"Local oestrogen for vaginal atrophy in postmenopausal women","volume":"2016(8):CD001500","author":"Lethaby","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.maturitas.2026.108929_bb0080","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JOP.2011.000352","article-title":"Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator","volume":"8","author":"Wills","year":"2012","journal-title":"J. Oncol. Pract."},{"issue":"2","key":"10.1016\/j.maturitas.2026.108929_bb0085","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ajog.2019.08.043","article-title":"Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy","volume":"222","author":"Crean-Tate","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.maturitas.2026.108929_bb0090","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00042192-200205000-00006","article-title":"Treatment of urogenital atrophy with low-dose estradiol: preliminary results","volume":"9","author":"Santen","year":"2002","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.maturitas.2026.108929_bb0095","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/AOG.0000000000004899","article-title":"General approaches to medical management of menstrual suppression: ACOG clinical consensus No. 3","volume":"140","author":"American College of Obstetricians and Gynecologists'\u2019 Committee on Clinical Consensus\u2013Gynecology","year":"2022","journal-title":"Obstet. Gynecol."},{"issue":"14","key":"10.1016\/j.maturitas.2026.108929_bb0100","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1200\/JCO.2013.53.9411","article-title":"Interpreting plasma estrogen levels in breast cancer: caution needed","volume":"32","author":"Folkerd","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.maturitas.2026.108929_bb0105","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10549-024-07564-8","article-title":"Effects of vaginal estrogen on serum estradiol during aromatase inhibitor therapy in breast cancer patients with vulvovaginal atrophy: a prospective trial","volume":"210","author":"Faltinov\u00e1","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.maturitas.2026.108929_bb0110","first-page":"643","article-title":"Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance)","volume":"26","author":"Barton","year":"2018","journal-title":"Support Care Cancer"},{"issue":"14","key":"10.1016\/j.maturitas.2026.108929_bb0115","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.3390\/cancers15143647","article-title":"Revisiting estrogen for the treatment of endocrine-resistant breast cancer: novel therapeutic approaches","volume":"15","author":"Shete","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.maturitas.2026.108929_bb0120","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/bjc.2013.520","article-title":"Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study","volume":"109","author":"Iwase","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.maturitas.2026.108929_bb0125","first-page":"643","article-title":"Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance)","volume":"26","author":"Barton","year":"2018","journal-title":"Support Care Cancer"},{"issue":"7","key":"10.1016\/j.maturitas.2026.108929_bb0130","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jnci\/dji071","article-title":"Stockholm breast Cancer study group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial","volume":"97","author":"von Schoultz","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"issue":"9407","key":"10.1016\/j.maturitas.2026.108929_bb0135","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(04)15493-7","article-title":"HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped","volume":"363","author":"Holmberg","year":"2004","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.maturitas.2026.108929_bb0140","first-page":"S182","article-title":"Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients--design and baseline data \u2018LIBERATE\u2019 trial","volume":"16","author":"Kenemans","year":"2007","journal-title":"Breast"},{"issue":"9","key":"10.1016\/j.maturitas.2026.108929_bb0145","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1002\/cncr.10913","article-title":"Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study","volume":"95","author":"Vassilopoulou-Sellin","year":"2002","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.maturitas.2026.108929_bb0150","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10549-021-06436-9","article-title":"Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis","volume":"191","author":"Poggio","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.maturitas.2026.108929_bb0155","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0378-5122(01)00211-0","article-title":"A prospective study on women with a history of breast cancer and with or without estrogen replacement therapy","volume":"39","author":"Marttunen","year":"2001","journal-title":"Maturitas"},{"issue":"10","key":"10.1016\/j.maturitas.2026.108929_bb0160","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djac112","article-title":"Systemic or vaginal hormone therapy after early breast Cancer: a Danish observational cohort study","volume":"114","author":"Cold","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.maturitas.2026.108929_bb0165","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1080\/13697130500345216","article-title":"Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer","volume":"8","author":"Dimitrakakis","year":"2005","journal-title":"Climacteric"},{"issue":"4","key":"10.1016\/j.maturitas.2026.108929_bb0170","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.GME.0000061806.76067.E9","article-title":"Estrogen replacement therapy in breast cancer survivors: a matched-controlled series","volume":"10","author":"Decker","year":"2003","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.maturitas.2026.108929_bb0175","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/AOG.0000000000005294","article-title":"Safety of vaginal estrogen therapy for genitourinary syndrome of menopause in women with a history of breast Cancer","volume":"142","author":"Agrawal","year":"2023","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.maturitas.2026.108929_bb0180","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1001\/jamaoncol.2023.4508","article-title":"Vaginal estrogen therapy use and survival in females with breast Cancer","volume":"10","author":"McVicker","year":"2024","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.maturitas.2026.108929_bb0185","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ajog.2024.10.054","article-title":"Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks","volume":"232","author":"Beste","year":"2025","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"19","key":"10.1016\/j.maturitas.2026.108929_bb0190","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.3390\/cancers16193267","article-title":"Menopausal hormone therapy in breast cancer survivors","volume":"16","author":"Culhane","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.maturitas.2026.108929_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2025.105820","article-title":"Estrogen receptor-low positive breast cancer: historical perspective and recent advancements","volume":"162","author":"Zhang","year":"2025","journal-title":"Hum. Pathol."},{"issue":"16","key":"10.1016\/j.maturitas.2026.108929_bb0200","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1200\/JCO-24-02263","article-title":"Endocrine therapy omission in estrogen receptor-low (1%-10%) early-stage breast Cancer","volume":"43","author":"Choong","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.maturitas.2026.108929_bb0205","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","article-title":"Differences in breast Cancer survival by molecular subtypes in the United States","volume":"27","author":"Howlader","year":"2018","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"19","key":"10.1016\/j.maturitas.2026.108929_bb0210","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-Cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.maturitas.2026.108929_bb0215","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamaoncol.2025.0178","article-title":"Prognostic and predictive insights from genomic assays for breast Cancer in diverse populations: a review","volume":"11","author":"Abdou","year":"2025","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.maturitas.2026.108929_bb0220","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/tbj.13859","article-title":"Multigene testing in breast cancer: what have we learned from the 21-gene recurrence score assay?","volume":"26","author":"Turashvili","year":"2020","journal-title":"Breast J."},{"issue":"16","key":"10.1016\/j.maturitas.2026.108929_bb0225","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1200\/JCO.22.00069","article-title":"Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast Cancer: ASCO guideline update","volume":"40","author":"Andre","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.maturitas.2026.108929_bb0230","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1200\/JCO.19.00948","article-title":"Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast Cancer: update of the ASCO endorsement of the Cancer Care Ontario guideline","volume":"37","author":"Henry","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.maturitas.2026.108929_bb0235","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-gene signature as an aid to treatment decisions in early-stage breast Cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.maturitas.2026.108929_bb0240","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1200\/JCO.22.00069","article-title":"Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast Cancer: ASCO guideline update","volume":"40","author":"Andre","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.maturitas.2026.108929_bb0245","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/1078-0432.CCR-20-2737","article-title":"Breast Cancer index predicts extended endocrine benefit to individualize selection of patients with HR+ early-stage breast Cancer for 10 years of endocrine therapy","volume":"27","author":"Noordhoek","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.maturitas.2026.108929_bb0250","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1470-2045(25)00152-4","article-title":"Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study","volume":"26","author":"Blondeaux","year":"2025","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.maturitas.2026.108929_bb0260","first-page":"e16","article-title":"Menon U; Royal College of Obstetricians and Gynaecologists. Risk-reducing Salpingo-oophorectomy and the use of hormone replacement therapy below the age of natural menopause: scientific impact paper no. 66 October 2021: scientific impact paper no. 66","volume":"129","author":"Manchanda","year":"2022","journal-title":"BJOG"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512226001064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512226001064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T21:25:26Z","timestamp":1779485126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512226001064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":51,"alternative-id":["S0378512226001064"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2026.108929","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Menopausal hormone therapy in breast cancer survivors: A review","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2026.108929","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108929"}}